Results 11 to 20 of about 413,339 (385)
Exosomal delivery of doxorubicin enables rapid cell entry and enhanced in vitro potency.
PLoS ONE, 2019 Doxorubicin is a chemotherapeutic agent that is commonly used to treat a broad range of cancers. However, significant cardiotoxicity, associated with prolonged exposure to doxorubicin, limits its continued therapeutic use.
Christina Schindler +7 more
doaj +2 more sources
Efficient chemotherapy of rat glioblastoma using Doxorubicin-loaded PLGA nanoparticles with different stabilizers [PDF]
, 2011 Background: Chemotherapy of glioblastoma is largely ineffective as the blood-brain barrier (BBB) prevents entry of most anticancer agents into the brain.
Bernreuther, Christian +6 more
core +14 more sources
Doxorubicin—An Agent with Multiple Mechanisms of Anticancer Activity
Cells, 2023 Doxorubicin (DOX) constitutes the major constituent of anti-cancer treatment regimens currently in clinical use. However, the precise mechanisms of DOX’s action are not fully understood.
M. Kciuk +6 more
semanticscholar +1 more source
International Journal on Biological Sciences, 2022 Cancer is a destructive disease that causes high levels of morbidity and mortality. Doxorubicin (DOX) is a highly efficient antineoplastic chemotherapeutic drug, but its use places survivors at risk for cardiotoxicity. Many studies have demonstrated that
C. Kong +7 more
semanticscholar +1 more source
Regulated cell death pathways in doxorubicin-induced cardiotoxicity
Cell Death and Disease, 2021 Doxorubicin is a chemotherapeutic drug used for the treatment of various malignancies; however, patients can experience cardiotoxic effects and this has limited the use of this potent drug.
E. Christidi, L. Brunham
semanticscholar +1 more source
Mitochondrial-Targeted Therapy for Doxorubicin-Induced Cardiotoxicity
International Journal of Molecular Sciences, 2022 Anthracyclines, such as doxorubicin, are effective chemotherapeutic agents for the treatment of cancer, but their clinical use is associated with severe and potentially life-threatening cardiotoxicity.
Bin Wu, K. Leung, E. Poon
semanticscholar +1 more source
Cardiovascular Diabetology, 2021 Background Empagliflozin (EMPA), a selective inhibitor of the sodium glucose co-transporter 2, reduced the risk of hospitalization for heart failure and cardiovascular death in type 2 diabetic patients in the EMPA‐REG OUTCOME trial.
V. Quagliariello +11 more
semanticscholar +1 more source
Science Signaling, 2022 Clinical use of doxorubicin (DOX) is limited because of its cardiotoxicity, referred to as DOX-induced cardiomyopathy (DIC). Mitochondria-dependent ferroptosis, which is triggered by iron overload and excessive lipid peroxidation, plays a pivotal role in
K. Abe +14 more
semanticscholar +1 more source
Molecules, 2022 Doxorubicin is a widely used and promising anticancer drug; however, a severe dose-dependent cardiotoxicity hampers its therapeutic value. Doxorubicin may cause acute and chronic issues, depending on the duration of toxicity.
R. A. Syahputra +4 more
semanticscholar +1 more source
Mitochondria-dependent ferroptosis plays a pivotal role in doxorubicin cardiotoxicity.
JCI Insight, 2020 Doxorubicin (DOX), a chemotherapeutic agent, induces a cardiotoxicity referred to as doxorubicin-induced cardiomyopathy (DIC). This cardiotoxicity often limits chemotherapy for malignancies and is associated with poor prognosis.
T. Tadokoro +11 more
semanticscholar +1 more source